Effect of ghrelin receptor antagonist on meal patterns in cholecystokinin type 1 receptor null mice

被引:8
作者
Lee, Jennifer [1 ]
Martin, Elizabeth [1 ]
Paulino, Gabriel [1 ]
de Lartigue, Guillaume [1 ]
Raybould, Helen E. [1 ]
机构
[1] UC Davis, Dept Anat Physiol & Cell Biol, Sch Vet Med, Davis, CA 95616 USA
关键词
Ghrelin; CCK; Nodose ganglia; c-fos; Neuronal activation; DIET-INDUCED OBESITY; VAGAL AFFERENT NEURONS; RAT ARCUATE NUCLEUS; HIGH-FAT DIET; CCK1; RECEPTOR; SHORT-TERM; EXPRESSION; APPETITE; BRAIN; HYPERPHAGIA;
D O I
10.1016/j.physbeh.2011.01.018
中图分类号
B84 [心理学];
学科分类号
04 ; 0402 ;
摘要
Vagal afferent neurons (VAN) express the cholecystokinin (CCK) type 1 receptor (CCK(1)R) and, as predicted by the role of CCK in inducing satiation, CCK(1)R-/- mice ingest larger and longer meals. However, after a short fast, CCK(1)R-/- mice ingesting high fat (HF) diets initiate feeding earlier than wild-type mice. We hypothesized that the increased drive to eat in CCK(1)R-/- mice eating HF diet is mediated by ghrelin, a gut peptide that stimulates food intake. The decrease in time to first meal, and the increase in meal size and duration in CCK(1)R-/- compared to wild-type mice ingesting high fat (HF) diet were reversed by administration of GHSR1a antagonist D-(Lys3)-GHRP-6 (p<0.05). Administration of the GHSR1a antagonist significantly increased expression of the neuropeptide cocaine and amphetamine-regulated transcript (CART) in VAN of HF-fed CCK(1)R-/- but not wild-type mice. Administration of the GHSR1a antagonist decreased neuronal activity measured by immunoreactivity for fos protein in the nucleus of the solitary tract (NTS) and the arcuate nucleus of both HF-fed wild-type and CCK(1)R-/- mice. The data show that hyperphagia in CCK(1)R-/- mice ingesting HF diet is reversed by blockade of the ghrelin receptor, suggesting that in the absence of the CCK(1)R, there is an increased ghrelin-dependent drive to feed. The site of action of ghrelin receptors is unclear, but may involve an increase in expression of CART peptide in VAN in HF-fed CCK(1)R-/- mice. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:181 / 187
页数:7
相关论文
共 50 条
  • [31] A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma
    Tucker, Robin D.
    Ciofoaia, Victor
    Nadella, Sandeep
    Gay, Martha D.
    Cao, Hong
    Huber, Matthew
    Safronenka, Anita
    Shivapurkar, Narayan
    Kallakury, Bhaskar
    Kruger, Annie J.
    Kroemer, Alexander H. K.
    Smith, Jill P.
    DIGESTIVE DISEASES AND SCIENCES, 2020, 65 (01) : 189 - 203
  • [32] Cholecystokinin Receptor Antagonist Therapy Decreases Inflammation and Fibrosis in Chronic Pancreatitis
    Nadella, Sandeep
    CiofoaiaL, Victor
    Cao, Hong
    Kallakury, Bhaskar
    Tucker, Robin D.
    Smith, Jill P.
    DIGESTIVE DISEASES AND SCIENCES, 2020, 65 (05) : 1376 - 1384
  • [33] Vagal afferent cholecystokinin receptor activation is required for glucagon-like peptide-1-induced satiation
    Vana, Vasiliki
    Laerke, Michelle K.
    Rehfeld, Jens F.
    Arnold, Myrtha
    Dmytriyeva, Oksana
    Langhans, Wolfgang
    Schwartz, Thue W.
    Hansen, Harald S.
    DIABETES OBESITY & METABOLISM, 2022, 24 (02) : 268 - 280
  • [34] A Novel Ghrelin Receptor Antagonist May Serve as a Therapeutic Target for Alcoholism
    Tapocik, Jenica
    Pilling, Andrew
    Pincus, Alexandra
    Frable, Christian
    Akhlaghi, Fatemeh
    Heilig, Markus
    Leggio, Lorenzo
    NEUROPSYCHOPHARMACOLOGY, 2014, 39 : S597 - S597
  • [35] Effect of Growth Hormone Secretagogue Receptor Deletion on Growth, Pulsatile Growth Hormone Secretion, and Meal Pattern in Male and Female Mice
    Labarthe, Alexandra
    Zizzari, Philippe
    Fiquet, Oriane
    Lebrun, Nicolas
    Veldhuis, Johannes D.
    Roelfsema, Ferdinand
    Chauveau, Christophe
    Bohlooly-Y, Mohammad
    Epelbaum, Jacques
    Tolle, Virginie
    NEUROENDOCRINOLOGY, 2022, 112 (03) : 215 - 234
  • [36] The Tumor Suppressive Effect of Angiotensin II Type 1 Receptor Antagonist in a Murine Osteosarcoma Model
    Wasa, Junji
    Sugiura, Hideshi
    Kozawa, Eiji
    Kohyama, Keishi
    Yamada, Kenji
    Taguchi, Osamu
    ANTICANCER RESEARCH, 2011, 31 (01) : 123 - 127
  • [37] Metabolic Actions of the Type 1 Cholecystokinin Receptor: Its Potential as a Therapeutic Target
    Miller, Laurence J.
    Desai, Aditya J.
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2016, 27 (09) : 609 - 619
  • [38] Anticonvulsant effect of a ghrelin receptor agonist in 6Hz corneally kindled mice
    Coppens, Jessica
    Aourz, Najat
    Walrave, Laura
    Fehrentz, Jean-Alain
    Martinez, Jean
    De Bundel, Dimitri
    Portelli, Jeanelle
    Smolders, Ilse
    EPILEPSIA, 2016, 57 (09) : E195 - E199
  • [39] Inhibition of ghrelin-induced feeding in rats by pretreatment with a novel dual orexin receptor antagonist
    So, Mariko
    Hashimoto, Hirofumi
    Saito, Reiko
    Yamamoto, Yukiyo
    Motojima, Yasuhito
    Ueno, Hiromichi
    Sonoda, Satomi
    Yoshimura, Mitsuhiro
    Maruyama, Takashi
    Kusuhara, Koichi
    Ueta, Yoichi
    JOURNAL OF PHYSIOLOGICAL SCIENCES, 2018, 68 (02) : 129 - 136
  • [40] REDUCED ANTICIPATORY LOCOMOTOR RESPONSES TO SCHEDULED MEALS IN GHRELIN RECEPTOR DEFICIENT MICE
    Blum, I. D.
    Patterson, Z.
    Khazall, R.
    Lamont, E. W.
    Sleeman, M. W.
    Horvath, T. L.
    Abizaid, A.
    NEUROSCIENCE, 2009, 164 (02) : 351 - 359